Skip to main content

Home/ Dr. Goodyear/ Group items tagged events

Rss Feed Group items tagged

Filter: All | Bookmarks | Topics Simple Middle
Nathan Goodyear

The endurance athletes heart: acute stress and chronic adaptation -- George et al. 46 (... - 0 views

bjsm.bmj.com/...i29.full

heart health endurance athletes endurance exercise athletes athletic heart

shared by Nathan Goodyear on 10 Jan 15 - No Cached
  • Nathan Goodyear on 10 Jan 15
     
    acute and chronic heart changes to endurance training/events.
Nathan Goodyear

Lipoprotein(a), Hormone Replacement Therapy and Risk of Future Cardiovascular Events - 0 views

www.ncbi.nlm.nih.gov/...PMC2958092

hormone replacement therapy cardiovascular disease events risk Lp(a) lipoprotein(a) lipoproteins CVD women HT HRT hormones

shared by Nathan Goodyear on 26 Aug 14 - No Cached
  • Nathan Goodyear on 26 Aug 14
     
    study finds HT reduced Lp(a) in women and reduced the Lp(a) association with CVD.  Women not on HT in this study had higher Lp(a) versus those on HT.
Nathan Goodyear

http://qjmed.oxfordjournals.org/content/early/2014/08/18/qjmed.hcu173.full.pdf#page=1&v... - 0 views

qjmed.oxfordjournals.org/...qjmed.hcu173.full.pdf

Testosterone therapy steroids bodybuilding cardiovascular disease risk men male hormone hormones

shared by Nathan Goodyear on 21 Aug 14 - No Cached
  • Nathan Goodyear on 21 Aug 14
     
    Case study published ahead of print--chronic Testosterone use in body building and cardiovascular event in a young man.
Nathan Goodyear

http://www.msma.org/docs/communications/momed/Excessive_Endurance_Exercise_and_Heart_Di... - 0 views

www.msma.org/..._Disease_MOMED_JulyAug2012.pdf

heart disease endurance exercise exercise marathons triathlon endurance athletes heart health disease

shared by Nathan Goodyear on 10 Jan 15 - No Cached
  • Nathan Goodyear on 10 Jan 15
     
    great review of data on cardiac damage associated with extreme endurance training.  These EEEs, that they are called, are rare in those < 40 and usually involved genetic defects.  This article points to aggressive preventive testing in those > 50.
Nathan Goodyear

25-Hydroxyvitamin D, 1,25-Dihydroxyvitamin D and Postoperative Outcome in Cardiac Surge... - 0 views

press.endocrine.org/...jc.2014-3013

vitamin D CVD cardiovascular disease heart health cerebrovascular CVA surgery

shared by Nathan Goodyear on 14 Jan 15 - No Cached
  • Nathan Goodyear on 14 Jan 15
     
    low vitamin D predicts increased risk of Major adverse cardiac and/or cerebrovascular events after cardiac surgery.  The definition of low D was <30.  A better study would have been to stratify by 10s the risk.
Nathan Goodyear

Hypertonic (3%) sodium chloride for emergent treatment of exercise-... - PubMed - NCBI - 0 views

www.ncbi.nlm.nih.gov/...17465635

endurance athletes exercise induced hyponatremia hyponatremia marathon runners athletes SIADH

shared by Nathan Goodyear on 27 Jan 15 - No Cached
  • Nathan Goodyear on 27 Jan 15
     
    event over hydration with under renal excretion can lead to hyponatremia.  SIADH and resultant increased ECW is involved.  Weight is an adequate means to evaluate--no weight loss and/or weight gain may suggest fluid overload and potential hyponatremia.
Nathan Goodyear

http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1332190/pdf/brjsmed00019-0063.pdf - 0 views

www.ncbi.nlm.nih.gov/...brjsmed00019-0063.pdf

endurance exercise endurance exercise endurance athletes athlete athletes marathon IV fluids intravenous

shared by Nathan Goodyear on 15 Jan 15 - No Cached
  • Nathan Goodyear on 15 Jan 15
     
    study finds IV hydration with glucose and larger volume did not recover as well as those with 100 ml  of IV fluids.  This conclusion is incomplete as the time differences between the 2 groups was significant--group 2 (2.5 L fluid group) finished much faster and studies have shown that these endurance athletes are more prone to dehydration, more significant weight loss, adverse effects from the event.  This likely explains the difference between the 2 groups.
Nathan Goodyear

https://www.cayugamed.org/docs/Nutrition_Update_for_the_Ultraendurance_Athlete%208.pdf - 0 views

www.cayugamed.org/...Ultraendurance_Athlete%208.pdf

endurance athletes endurance exercise nutrition athletes athlete

shared by Nathan Goodyear on 10 Jan 15 - No Cached
  • Nathan Goodyear on 10 Jan 15
     
    Nutrition for ultra endurance.  To be read.
Nathan Goodyear

Testosterone level in men with type 2 diabetes mellitus and related metabolic... - 0 views

www.ncbi.nlm.nih.gov/...PMC4364844

low T low Testosterone Diabetes Testosterone men male hormones metabolic syndrome

shared by Nathan Goodyear on 30 Mar 15 - No Cached
  • defined by consistent symptoms and signs of androgen deficiency, and an unequivocally low serum testosterone level
  • the threshold serum testosterone level below which adverse clinical outcomes occur in the general population is not known
  • most population-based studies use the serum testosterone level corresponding to the lower limit, quoted from 8.7 to 12.7&nbsp;nmol/L, of the normal range for young Caucasian men as the threshold
    • Nathan Goodyear
      Nathan Goodyear on 31 Mar 15
       
      this equals 251 to 366 in serum Total Testosterone
  • ...57 more annotations...
  • Researchers tried to examine whether serum total or free testosterone would be a better/more reliable choice when studying the effect of testosterone. The results were mixed. Some reported significant associations of both serum total and free testosterone level with clinical parameters25, whereas others reported that only serum free testosterone26 or only serum total testosterone6 showed significant associations.
  • −0.124&nbsp;nmol/L/year in serum total testosterone
    • Nathan Goodyear
      Nathan Goodyear on 31 Mar 15
       
      this equates to a 4 ng/dl decline annually in total Testosterone.
  • In experimental studies, androgen receptor knockout mice developed significant insulin resistance rapidly
  • In mouse models, testosterone promoted differentiation of pluripotent stem cells to the myogenic lineage
  • testosterone decreased insulin resistance by enhancing catecholamine induced lipolysis in&nbsp;vitro, and reducing lipoprotein lipase activity and triglyceride uptake in human abdominal tissue in&nbsp;vivo
  • by promoting lipolysis and myogenesis, testosterone might lead to improved insulin resistance
  • testosterone regulated skeletal muscle genes involved in glucose metabolism that led to decreased systemic insulin resistance
  • In the liver, hepatic androgen receptor signaling inhibited development of insulin resistance in mice
  • independent and inverse association of testosterone with hepatic steatosis shown in a cross-sectional study carried out in humans
  • In short, androgen improves insulin resistance by changing body composition and reducing body fat.
  • Although a low serum testosterone level could contribute to the development of obesity and type&nbsp;2 diabetes through changes in body composition, obesity might also alter the metabolism of testosterone
  • In obese men, the peripheral conversion from testosterone to estrogen could attenuate the amplitude of luteinizing hormone pulses and centrally inhibit testosterone production
  • leptin, an adipokine, has been shown to be inversely correlated with serum testosterone level in men
  • Leydig cells expressed leptin receptors and leptin has been shown to inhibit testosterone secretion, suggesting a role of obesity and leptin in the pathogenesis of low testosterone
    • Nathan Goodyear
      Nathan Goodyear on 31 Mar 15
       
      So what is "unequivocal"?
  • Baltimore Longitudinal Study of Aging (BLSA) cohort made up of 3,565 middle-class, mostly Caucasian men from the USA, the incidence of low serum total testosterone increased from approximately 20% of men aged over 60&nbsp;years, 30% over 70&nbsp;years, to 50% over 80&nbsp;years-of-age
  • 30–44% sex hormone binding globulin (SHBG)-bound testosterone and 54–68% albumin-bound testosterone
  • As the binding of testosterone to albumin is non-specific and therefore not tight, the sum of free and albumin-bound testosterone is named bioavailable testosterone, which reflects the hormone available at the cellular level
  • Serum total testosterone is composed of 0.5–3.0% of free testosterone unbound to plasma proteins
  • alterations in SHBG concentration might affect total serum testosterone level without altering free or bioavailable testosterone
  • listed in Table​T
  • A significant, independent and longitudinal effect of age on testosterone has been observed with an average change of −0.124&nbsp;nmol/L/year in serum total testosterone28. The same trend has been shown in Europe and Australia
  • Asian men residing in HK and Japan, but not those living in the USA, had 20% higher serum total testosterone than in Caucasians living in the USA, as shown in a large multinational observational prospective cohort of the Osteoporotic Fractures in Men Study
  • subjects with chronic diseases consistently had a 10–15% lower level compared with age-matched healthy subjects
  • In Caucasians, the mean serum total testosterone level for men in large epidemiological studies has been reported to range from 15.1 to 16.6&nbsp;nmol/L
  • Asians, higher values, ranging from 18.1 to 19.1&nbsp;nmol/L, were seen in Korea and Japan
  • Chinese middle-aged men reported a similar mean serum testosterone level of 17.1&nbsp;nmol/L in 179 men who had a family history of type&nbsp;2 diabetes and 17.8&nbsp;nmol/L in 128 men who had no family history of type&nbsp;2 diabetes
  • The reduction of total testosterone was 0.4% per year in both groups
  • HK involving a cohort of 1,489 community-dwelling men with a mean age of 72&nbsp;years, a mean serum total testosterone of 19.0&nbsp;nmol/L was reported
  • pro-inflammatory factors, such as tumor necrosis factor-α in the testes, could locally inhibit testosterone biosynthesis in Leydig cells47, and testosterone treatment in men was shown to reduce the level of tumor necrosis factor-α
  • In Asians, a genetic deletion polymorphism of uridine diphosphate-glucuronosyltransferase UGT2B17 was associated with reduced androgen glucuronidation. This resulted in higher level of active androgen in Asians as compared to Caucasians, as Caucasians' androgen would be glucuronidated into inactive forms faster.
  • Compared with Caucasians, the frequency of this deletion polymorphism of UGT2B17 was 22-fold higher in Asian subjects
  • Other researchers have suggested that environmental, but not genetic, factors influenced serum total testosterone
  • The basal and ligand-induced activity of the AR is inversely associated with the length of the CAG repeat chain
  • In the European Male Aging Study, increased estrogen/androgen ratio in association with longer AR CAG repeat was observed
  • a smaller number of AR CAG repeat had been shown to be associated with benign prostate hypertrophy and faster prostate growth during testosterone treatment
  • In India, men with CAG ≤19 had increased risk of prostate cancer
  • the odds of having a short CAG repeat (≤17) were substantially higher in patients with lymph node-positive prostate cancer than in those with lymph node-negative disease or in the general population
  • assessing the polymorphism at the AR level could be a potential tool towards individualized assessment and treatment of hypogonadism.
  • In elderly men, there was reduced testicular response to gonadotropins with suppressed and altered pulsatility of the hypothalamic pulse generator
  • a significant, independent and longitudinal effect of age on serum total testosterone level had been observed
  • A significant graded inverse association between serum testosterone level and insulin levels independent of age has also been reported in Caucasian men
  • Low testosterone is commonly associated with a high prevalence of MES
  • most studies showed that changes in serum testosterone level led to changes in body composition, insulin resistance and the presence of MES, the reverse might also be possible
  • MES predicted a 2.6-fold increased risk of development of low serum testosterone level independent of age, smoking and other potential confounders
  • Other prospective studies have shown that development of MES accelerated the age-related decline in serum testosterone level
  • In men with type&nbsp;2 diabetes, changes in serum testosterone level over time correlated inversely with changes in insulin resistance
  • weight loss by either diet control or bariatric surgery led to a substantial increase in total testosterone, especially in morbidly obese men, and the rise in serum testosterone level was proportional to the amount of weight lost
  • To date, published clinical trials are small, of short duration and often used pharmacological, not physiological, doses of testosterone
  • In the population-based Osteoporotic Fractures in Men Study cohort from Sweden, men in the highest quartile of serum testosterone level had the lowest risk of cardiovascular events compared with men in the other three quartiles (hazard ratio [HR] 0.70
  • low serum total testosterone was associated with a significant fourfold higher risk of cardiovascular events when comparing men from the lowest testosterone tertile with those in the highest tertile
  • Shores et&nbsp;al. were the first to report that low serum testosterone level, including both serum total and free testosterone, was associated with increased mortality
  • low serum total testosterone predicted increased risk of cardiovascular mortality with a HR of 1.38
  • low serum total testosterone increased all-cause (HR 1.35, 95% CI 1.13–1.62, P&nbsp;&lt;&nbsp;0.001) and cardiovascular mortality (HR 1.25
  • European Association for the Study of Diabetes 2013 suggested there was an inverse relationship between serum testosterone level and acute myocardial infarction
  • Diabetic men in the highest quartile of serum total testosterone had a significantly reduced risk of acute MI when compared with those in the lower quartiles
  • serum total testosterone level in the middle two quartiles at baseline predicted reduced incidence of death compared with having the highest and lowest levels
  • Nathan Goodyear on 30 Mar 15
     
    Nice review of Testosterone levels and some of the evidence linking Diabetes with low T.  However, the conclusion by the authors regarding what is causing the low T in men with Diabetes is baffling.  The literature does not point to one cause, it is clearly multifactorial--obesity, inflammation, high aromatase activity...I would suggest the authors continue their readings in the manner.
Nathan Goodyear

http://circ.ahajournals.org/content/109/7/837.full.pdf - 0 views

circ.ahajournals.org/...837.full.pdf

LP-PLA2 lipoprotein-associated phospholipase A2 CVD cardiovascular disease heart heath CHD hsCRP

shared by Nathan Goodyear on 15 Apr 15 - No Cached
  • Nathan Goodyear on 15 Apr 15
     
    LP-PLA2 (Lipoprotein-Associated Phospholipase A2) with hs-CRP are associated with increased CHD events in those with low LDL-C.
wheelchairindia9

A Friendly Tricycle For The Disabled Users - 0 views

onlywheelchair.blogspot.in/...cle-for-disabled-users_14.html

A Friendly Tricycle For The Disabled Users disability tricycle designed tricycles lean steer handcycles hand driven tricycle wheel configurations

shared by wheelchairindia9 on 15 Apr 15 - No Cached
  • wheelchairindia9 on 15 Apr 15
     
    Those of all ages whose physical disabilities restrict their movement, affect their ability to earn a living or become valued members of society. Specially designed tricycles provide a mode of transport for the physically disabled allowing them much sought after independence and an opportunity for self support. The tricycles will enable freedom of movement and less dependency on others. Most of the people who depend on these tricycles are daily wage workers who have to travel long distances every day. The regular tricycles have no suspension and the riders are prone to spinal injuries. Most of them also cannot afford good medical care, and driving these tricycles for a long time affects. To deal with the problem, come up with a model tricycle that can be very useful to people who have a disability in their lower limbs, but a strong torso. The Handy tricycle to provide the ideal cycling experience for users advancement of upper body strength and toning for athletic events. Especially valuable to triathletes and challenged, it provides the perfect way to get in shape and stay that way. The tricycle achieves the true convenience of transportation while providing easy-to-use pedaling, steering and breaking controls. These are amongst the top selling handcycles on the market today. Handy is available in upright and recumbent versions. Hand powered front wheel drive. An internal hub-based gear shifting system is built into the front wheel.This provides ultra smooth shifting and is virtually maintenance-free. The entire front frame section is removable and connects easily, quickly and securely using a bolt-on system. The seat can be repositioned quickly and easily to allow the rider to achieve an optimally efficient distance between seat and handlebars.The rear wheels are removed using a single finger push system, allowing the bike to be broken down very quickly. Defined by two ways: Fork steer: It represent the majority of handcycles. They work well for both low
Nathan Goodyear

Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblasti... - 0 views

ascopubs.org/...JCO.2018.79.0139

Hodgkin's lymphoma Hodgkin's disease lymphoma immunotherapy cancer chemotherapy monoclonal antibodies

shared by Nathan Goodyear on 13 Sep 18 - No Cached
  • Nathan Goodyear on 13 Sep 18
     
    monoclonal Ab used in sequence with AVD found to have event-free survival, progression-free survival, and overal survival rates of 80%, 84%, and 93% respectively in older adults with Hodgkin's lymphoma.
Nathan Goodyear

Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multi... - 0 views

www.ncbi.nlm.nih.gov/...PMC5809128

cancer anal cancer nivolumab immunotherapy

shared by Nathan Goodyear on 13 Jul 18 - No Cached
  • Patients received a median of six doses of nivolumab
  • four of the first 12 patients had partial responses
  • Nine (24% [95% CI 15–33]) of 37 patients achieved a response (seven partial responses and two complete responses
  • ...16 more annotations...
  • no treatment-related deaths
  • the most common adverse events were anaemia (26 [70%]), fatigue (25 [68%]), and rash
  • hypothyroidism
  • hypothyroidism
  • nivolumab-related autoimmune hypothyroidism, which resolved after a short course of corticosteroids
  • No grade 3 or 4 adverse events occurred
  • Nivolumab resulted in objective responses in 24% of patients with metastatic SCCA
  • Historically, doublet chemotherapy with cisplatin and fluorouracil has been the most common treatment for patients with metastatic SCCA
  • our results suggest that immune checkpoint blockade agents might extend overall survival beyond currently available therapies, especially if provided early in the disease treatment course
  • the dose of nivolumab we used differs from the 2016 recommendation of a fixed 240 mg every 2 weeks
  • 25% of patients develop distant metastases
  • most patients with localised SCCA are cured by chemoradiation
  • More than 90% of cases of SCCA are linked to prior infection with human papillomavirus (HPV)
  • Within tumour cells, HPV oncoproteins are immunogenic and can trigger an anti-tumour host immune response by recruitment of tumour-infiltrating lymphocytes
  • Tumour cells express PD-L1 and, on binding its inhibitory receptor PD-1 on the surface of T cells, downregulate T-cell activation and thwart the local anti-tumour immune response
  • Nivolumab is a humanised monoclonal antibody against PD-1 that disrupts this interaction, enabling T-cell cytotoxicity. It has activity as a monotherapy in advanced solid cancers, such as head and neck cancer, melanoma, non-small-cell lung cancer, and renal cell carcinoma
  • Nathan Goodyear on 13 Jul 18
     
    study finds nivolumab helpful in some patients with surgically unresectable or metastatic anal cancer.  The dose used was 3 mg/kg every 2 weeks. 
Nathan Goodyear

Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on g... - 0 views

www.ncbi.nlm.nih.gov/...PMC4741919

adenoid cystic carcinoma

shared by Nathan Goodyear on 03 Oct 18 - No Cached
  • Cisplatin and 5-FU or CAP (cisplatin, doxorubicin, and cyclophosphamide) regimens can be used for combination chemotherapy
  • patients with advanced salivary gland malignancy treated with the CAP regimen achieved partial response (PR) or stable disease (SD) rates of 67% (8 out of 12 patients)
  • Agents commonly given as monotherapy for treating ACC are cisplatin, mitoxantrone, epirubicin, vinorelbine, paclitaxel, and gemcitabine. However, few of these agents have shown efficacy
  • ...23 more annotations...
  • single agent mitoxantrone or vinorelbine were recommended as reasonable choices
  • ACC is subdivided into 3 histological groups based on solid components of the tumor including cribriform, tubular, and solid
  • Cribriform and tubular ACCs usually exhibit a more indolent course, whereas the solid subtype is associated with worse prognosis
  • ACC consists of two different cell types: inner luminal epithelial cells and outer myoepithelial cells
  • epithelial cells express c-kit, cox-2 and Bcl-2
  • myoepithelial cells express EGFR and MYB
  • a balanced translocation of the v-myb avian myeloblastosis viral oncogene homolog-nuclear factor I/B (MYB-NFIB) is considered to be a signature molecular event of ACC oncogenesis
  • As a transcription factor, MYB is known to modulate multiple genetic downstream targets involved in oncogenesis, such as cox-2, c-kit, Bcl-2 and BclX
  • Various signaling cascades are essential for cancer cells to survive and grow. The PI3K/Akt/mTOR pathway is one of them
  • This pathway regulates cell survival and growth and is upregulated in many cancers
  • Mutations in genes associated with DNA repair are frequently found in familial cancer syndromes, such as hereditary breast-ovarian cancer syndrome (HBOC), hereditary non-polyposis colorectal cancer (HNPCC, also called Lynch syndrome) and Li-Fraumeni syndrome [30, 31]. These mutations were also reported in non-hereditary cancers
  • 70% of ACC samples (58 of 84) were found to have genetic alterations in the MYB/MYC pathway, indicating that changes in this pathway are crucial in ACC pathogenesis
  • The second most frequently mutated pathway was involved in chromatin remodeling (epigenetic modification), a pathway that includes multiple histone related proteins, and was altered in 44% of samples
  • C-kit
  • VEGF, iNOS and NF-κB were noted to be highly expressed in ACC cells as compared to normal salivary gland cells
  • members of the SOX family, such as SOX 4 and SOX10, are overexpressed in ACC
  • FABP7 (Fatty acid binding protein 7) and AQP1 (Aquaporin 1) tend to be overexpressed in ACC cell lines
  • considerable variability in HER2 overexpression ranging from 0–58% in patients with ACC
  • the study with cetuximab and concurrent chemoradiation or chemotherapy showed the highest ORR (total 43%, 9.5% CR and 33% PR), but this regimen was only given to the EGFR positive patients
  • Cancer immunotherapy can be classified into 3 major groups. Active immunization using anti-tumor vaccines to induce and recruit T cells, passive immunization based on monoclonal antibodies, and adoptive cell transfer to expand tumor-reactive autologous T cells ex vivo and then reintroduce these cells into the same individual
  • LAK cells showed cytotoxicity against ACC cells
  • cytokine-induced cell apoptosis and the cytotoxic effect of the LAK cells contributed to tumor regression
  • molecular finding of the MYB-NFIB fusion gene has the greatest potential to target what appears to be a fundamental event in disease pathogenesis
  • Nathan Goodyear on 03 Oct 18
     
    good review of adenoid cystic carcinoma
Nathan Goodyear

Statin use and risk of diabetes mellitus - 0 views

www.ncbi.nlm.nih.gov/...PMC4360430

statin statin therapy diabetes insulin resistance GLUT4 HgbA1c

shared by Nathan Goodyear on 04 Oct 17 - No Cached
  • An increase in new onset diabetes, i.e., 3% in statin arm and 2.4% in placebo arm was reported. This was accompanied by increase in median value of glycated haemoglobin and was one of the earlier studies to report the increase in new onset diabetes in patients on statins
  • Even after adjustment for potential confounders, statin therapy was associated with an increased risk of new-onset diabetes mellitus
  • Authors suggest that statin-induced diabetes mellitus is a medication class effect
  • ...10 more annotations...
  • Another study also reported that as compared to placebo, statin group showed a higher risk of physician reported incident diabetes and it was also observed that risk was higher in women as compared to men
  • Meta-analysis of randomized controlled trials by Sattar et al[25] involving 91140 non-diabetic patients showed that statin therapy was associated with 9% increased risk of incident diabetes
  • A number of studies showed dose dependent association between statin administration and incident diabetes
  • intensive dose of statins was associated with high incidence of new - onset diabetes
  • Treatment with atorvastatin and simvastatin may be associated with an increased risk of new onset diabetes as compared to pravastatin
  • Increased incidence of diabetes was seen with atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial
  • Increased insulin resistance secondary to statins was demonstrated in a prospective non randomised study in patients with coronary bypass surgery
  • downregulation of GLUT4
  • Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
  • Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
  • Nathan Goodyear on 04 Oct 17
     
    Great review article of the increased risk of worsening insulin resistance, glycated hemoglobin, and diabetes risk.  Atorvastatin appears to be the worst culprit.  Mechanism partially through a decrease in GLUT4.
Nathan Goodyear

Safety of Combined Treatment With Monoclonal Antibodies and Viscum album L Preparations - 0 views

www.ncbi.nlm.nih.gov/...PMC5950938

VAE mistletoe cancer monoclonal antibodies mAB IL-12 NK cells

shared by Nathan Goodyear on 06 Jun 18 - No Cached
  • Among the most encouraging mAb is trastuzumab, which targets the human epidermal growth factor receptor 2 and is indicated in the treatment of breast cancer
  • bevacizumab, which inhibits vascular endothelial growth factor and is indicated in the treatment of a range of diseases, including colorectal, lung, and ovarian cancer3; and cetuximab, which blocks the epidermal growth factor receptor and is indicated in the treatment of colorectal and lung cancer
  • Viscum album L (VA or European mistletoe) preparations are widely used as additive cancer therapy in Europe, especially in German-speaking countries, and have been associated with a reduction in chemotherapy-related adverse drug reactions and increased HRQL
  • ...6 more annotations...
  • leading to enhancement of interleukin-12 secretion and natural killer cell function
  • Helixor VA preparations
  • A multivariable GEE model indicated that the odds for patients experiencing an AE following mAb therapy were nearly 5 times higher compared with that for mAb plus VA
  • VA preparations (Iscador Ltd) did not inhibit chemotherapy-induced cytostasis or cytotoxicity and showed an additive inhibitory effect at higher concentrations of VA.
  • previous in vitro investigations have shown that VA preparations have either no or minor effects on a range of CYPs, suggesting that VA-drug interactions based on drug metabolism are unlikely
  • mAb do not undergo hepatic metabolism but undergo proteolytic catabolism throughout the body
  • Nathan Goodyear on 06 Jun 18
     
    VAE therapy found to reduce adverse events in those receiving monoclonal Ab therapy.
Nathan Goodyear

Weekly ascorbic acid infusion in castration-resistant prostate cancer patients: a singl... - 0 views

www.ncbi.nlm.nih.gov/...PMC5503969

IV vitamin C vitamin c prostate cancer

shared by Nathan Goodyear on 20 Aug 19 - No Cached
  • Nathan Goodyear on 20 Aug 19
     
    Look at this BS study. 60 grams!!! Create a study to underdose the patients and then declare the "alternative treatment" without evidence. They lack such an understanding of the pharmacokinetics of vitamin C. They also lack a basic experience with IV vitamin C! Also, serious adverse events with the 60 grams IVC?!?!?
Phiten Singapore

Thank You Attendees! - 0 views

plus.google.com/...j7hRZeo7Fkw

Phiten Roadshow Thank You Products Health Beauty Life style Fitness Wellbeing

shared by Phiten Singapore on 07 Mar 17 - No Cached
  • Phiten Singapore on 07 Mar 17
     
    Thank you to all the participants who join our roadshow which was at Waterway Point. Your participation makes the event more enjoyable and memorable. Go through the link: https://www.facebook.com/PhitenSGOfficial/videos/1476136799064785/
Nathan Goodyear

Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with meta... - 0 views

bmccancer.biomedcentral.com/...s12885-019-5696-z

IV vitamin C cancer vitamin C

shared by Nathan Goodyear on 21 May 19 - No Cached
  • Nathan Goodyear on 21 May 19
     
    Phase I study of vitamin C and FOLFOX or FOLFIRI. Numerous studies have shown the extremely high safety profile of IV vitamin C in cancer. The need to show the same thing time and time again borders on the insanity. The potential adverse events listed in this study is from the FOLFOX or FOLFIRI, not the vitamin C.
pharmacybiz

Award Categories - Pharmacy Business Awards 2023 - 0 views

pharmacybusinessawards.co.uk/categories

Pharmacy-Awards-2023 pharmacy-business Pharmacy-Business-Awards Pharmacy-Business-Conference Pharmacy-Excellence

shared by pharmacybiz on 23 Jun 23 - No Cached
  • pharmacybiz on 23 Jun 23
     
    Pharmacy Business will be hosting their annual awards event in the pharmacy calendar with a glittering ceremony to celebrate the very best of community pharmacy. The 23rd edition of the Pharmacy Business Awards will be on Wednesday 4 October 2023 in central London. The awards attract the biggest names in pharmacy, with heads of pharmacy organisations, CEOs of leading manufacturers and wholesalers, health officials and government ministers in attendance. We look forward to bringing together the shining lights of community pharmacy, who show the nation the unique services they continue to provide. All entries must be made on the official online entry form. Please select from the award categories by expanding the drop-down boxes below then click 'Enter now' by selecting the category you would like to enter. You can enter three categories. To complete your entry, agree to the terms and conditions then click the 'COMPLETE' button at the bottom of the page. All submissions must be made by Monday 7th July 2023. Please note only submitted entries will proceed to the judging stage. Nomination date 7th july 2023
« First ‹ Previous 81 - 100 of 172 Next › Last »
Showing 20▼ items per page